+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are investigating the effects of APL-3007 combined with SyfovrePegcetacoplan APL-2 in patients with geographic atrophy caused by age-related macular degeneration AMD. This Phase 2 randomized, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacodynamics of these treatments in this eye condition. The study involves multiple centers and uses a masked design to ensure unbiased results. Participants will be assigned to one of three groups two receiving different doses or frequencies of APL-3007 in combination with pegcetacoplan APL-2, and one receiving a placebo along with pegcetacoplan APL-2. The study will evaluate the treatments given as multidose regimens. The treatments focus on complement C3 inhibition to potentially impact disease progression. Throughout the study, participants will undergo assessments including artificial intelligence-based imaging to measure retinal pigment epithelium lesion area and photoreceptor degeneration, safety evaluations through adverse event reporting and visual acuity tests, and blood tests to assess serum markers. These evaluations occur over 12 months to monitor changes from baseline. Participants involvement includes regular visits for these assessments, with the study tracking treatment effects and safety over the duration.

Age: 60Years +All GendersPhase 2
78 locations
C

Actively Recruiting

Researchers are evaluating the investigational medicine BI 764524 for adults with moderate to severe non-proliferative diabetic retinopathy, an eye condition related to diabetes. The study aims to determine whether BI 764524 helps improve this condition and to identify the best treatment plan. This phase 2 trial randomly assigns participants to five groups to compare different dosing regimens and controls, including a group receiving aflibercept, an approved diabetic retinopathy treatment available only in the USA. Participants receive varying numbers of injections of BI 764524 in one eye over one year, with some visits involving sham injections that mimic the procedure without a needle to maintain blinding. One group receives only sham injections, and another group in the USA receives aflibercept or sham injections. The treatment period lasts 52 weeks, after which researchers evaluate improvements in eye severity and complications. Throughout the 1.5-year study, participants visit the study site at least 16 times for regular eye exams, vision tests, and imaging scans to monitor the eye condition and treatment effects. Researchers assess improvements using the Diabetic Retinopathy Severity Scale and watch for vision-threatening complications. Safety is monitored by tracking any adverse effects. The study helps understand how BI 764524 affects diabetic retinopathy over time.

Age: 18Years +All GendersPhase 2
90 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the Recharge Behavioral Therapy RBT intervention to reduce stress and depressive symptoms in caregivers of individuals with Alzheimers Disease and related dementia. This study is a phase 2 randomized trial comparing RBT delivered via a mobile app to a traditional educational and resource program. The goal is to support caregivers by assessing how these programs affect their mental well-being. Participants will be randomly assigned to one of two groups. One group will use the Caring Recharge mobile app containing the Recharge Behavioral Therapy program, while the other group will receive a traditional educational program that includes a downloadable workbook and online resources. Both interventions are behavioral and aim to provide support through different formats. During the study, participants will use their assigned program and researchers will measure outcomes related to depression and perceived stress at three months. The main tools used are the Center for Epidemiological Studies Depression Scale and the Perceived Stress Scale. The study allows for remote participation using smartphones or tablets, with data collected to evaluate the impact of these supportive care interventions on caregiver stress and depressive symptoms.

Age: 18Years +All GendersPhase 2
1 location
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a gene therapy called Ixo-vec compared to the drug aflibercept in people with neovascular wet age-related macular degeneration nAMD. This degenerative eye disease causes abnormal blood vessel growth under the retina and is a leading cause of vision loss in older adults. The study is a Phase 3 trial including both new and previous treatment patients and aims to see if Ixo-vec is not worse than aflibercept in improving vision. Participants will receive either a single injection of Ixo-vec or multiple injections of aflibercept in the eye. Both groups will begin with three monthly aflibercept injections then one group gets a single Ixo-vec injection and sham injections every 8 weeks, while the other group continues aflibercept every 8 weeks with a sham injection at week 1. The study lasts over a year, with key vision measurements taken around weeks 52 and 56. During the trial, participants will have regular eye exams and assessments of visual acuity and retinal thickness. Researchers will monitor safety, tolerability, and vision changes throughout the study. The main measurement is the average change in best corrected visual acuity at one year. Additional tests include eye imaging and quality of life questionnaires. Participation involves scheduled visits to track treatment effects and side effects over the study duration.

Age: 50Years +All GendersPhase 3
79 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
G

Actively Recruiting

This research aims to gather real-world data on the outcomes of Boston Scientific neurostimulation systems used for pain management in everyday clinical practice. It focuses on evaluating the long-term effectiveness, economic value, and technical performance of these commercially approved neurostimulation devices when used according to their instructions. Participants will undergo a trial period with a Boston Scientific neurostimulation system for pain. Those who experience positive results from the trial may then receive a permanent implant of the neurostimulation system. The therapy will be personalized based on the investigators judgment and routine site care, following the studys inclusion and exclusion criteria. During the study, participants will be monitored as they receive neurostimulation therapy in real-world settings. Researchers will collect information on treatment outcomes and device performance over time. The study spans from 2012 to 2035, allowing for long-term observation of participants using these neurostimulation systems for pain relief.

Age: 18Years +All Genders
118 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a single intravitreal injection of 4D-150 compared to aflibercept in adults with neovascular age-related macular degeneration nAMD. This Phase 3 randomized, double-masked trial includes a primary global cohort with completed enrollment and an ongoing Japan cohort. The study aims to understand visual acuity changes and treatment needs over time in this patient population. Participants are randomly assigned to receive either one dose of 4D-150 administered as a single intravitreal injection on Day 1 or aflibercept injections at scheduled visits. The study follows participants for up to 104 weeks to assess the need for additional aflibercept injections after the initial treatment. The trial includes safety and efficacy monitoring with comparisons between the study drug and the active comparator. During the trial, participants will undergo regular eye exams including measurements of best corrected visual acuity BCVA at 52 weeks and up to 104 weeks. Central subfield thickness and other anatomical features will be monitored using imaging techniques such as fluorescein angiography and optical coherence tomography. Researchers will track injection frequency, visual function, and eye health. The total participation duration may span over two years with ongoing assessments to evaluate treatment outcomes and safety.

Age: 50Years +All GendersPhase 3
126 locations
R

Actively Recruiting

Neovascular age-related macular degeneration nAMD, often called wet AMD, involves abnormal growth of new blood vessels in the retina, the light-sensitive tissue at the back of the eye. This research aims to evaluate the safety and effectiveness of Surabgene Lomparvovec, an investigational gene therapy, in adults aged 50 and older who have been previously treated for nAMD. Approximately 561 participants will be enrolled globally and randomized into three groups to compare different treatments. Participants will be assigned to one of three groups two groups receive a single subretinal injection of Surabgene Lomparvovec at different doses, and the third group receives Ranibizumab injections as needed throughout the study. Ranibizumab is given as an intravitreal injection into the jelly-like tissue inside the eye, while Surabgene Lomparvovec is delivered beneath the retina. The studys assessment period begins two weeks before randomization and follows participants for up to five years. During the study, participants will attend monthly visits at a hospital or clinic where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted to evaluate treatment effects. Researchers will track the annual rate of anti-VEGF injections and monitor adverse events over five years, along with changes in visual acuity. The study is designed to assess long-term treatment burden, safety, and preservation of vision in a real-world context.

Age: 50Years +All GendersPhase 3
138 locations
E

Actively Recruiting

Researchers are studying diabetic retinopathy DR, an eye condition caused by diabetes that damages blood vessels in the retina and can lead to vision loss. This trial evaluates surabgene lomparvovec sura-vec, a gene therapy given as a one-time injection into the suprachoroidal space SCS, aiming to treat non-proliferative DR without center-involved diabetic macular edema CI-DME and prevent vision-threatening events. The study includes Phase 2b, Phase 3, and a bilateral treatment portion with about 576 adult participants across the United States and Puerto Rico. Participants are randomly assigned to receive sura-vec plus prophylactic steroids or sham injections plus artificial tears in one eye during the Phase 2b and Phase 3 portions. Those receiving sham may later cross over to sura-vec treatment. In the bilateral portion, participants receive sura-vec and steroids in both eyes. Each participant receives a single injection per eye. Follow-up continues for up to five years after treatment to monitor outcomes and safety. Throughout the study, participants attend regular clinic visits for medical assessments, blood tests, and questionnaires to monitor the treatments effects and any side effects. Researchers will track diabetic retinopathy severity using the Diabetic Retinopathy Severity Scale DRSS and watch for vision-threatening events. Safety is closely monitored, including eye inflammation and other adverse events, with follow-up extending up to approximately two years for the bilateral portion and five years overall. Participants should expect a higher treatment burden than standard care.

Age: 18Years +All GendersPhase 2Phase 3
40 locations